metaEvidence - study list

meta|evidence oncology

Living systematic review and meta-analysis

malignant mesothelioma (mMS) - 2nd line (L2) 2
multiple myeloma

All treatments
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab plus lenalidomide and dexamethasone
pembrolizumab plus pomalidomide and dexamethasone

versus all
vs Immunosuppressant
vs lenalidomide based treatment
vs lenalidomide and dexamethasone
vs pomalidomide based treatment
vs pomalidomide and dexamethasone

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results

delta: difference in rate or median (if available)

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open